HIV testing as the bridge between awareness and acceptance of PrEP among MSM

Size: px
Start display at page:

Download "HIV testing as the bridge between awareness and acceptance of PrEP among MSM"

Transcription

1 PA_3 #08 HIV testing as the bridge between awareness and acceptance of PrEP among MSM Tsz Ho Kwan, BSc, MIET PhD Candidate in Public Health 1 June 2017

2 Content Background HIV epidemiology in Hong Kong MSM community PrEP Current situation of PrEP in Hong Kong Objective Methods Results Conclusions 2

3 Background 43% (3579/8410) of all HIV cases in Hong Kong were infected through homosexual/bisexual transmission ( ) Men who have sex with men (MSM) accounted for 61% newly diagnosed cases in 2016 Chan KCW. Press conference on local HIV/AIDS situation in [Presentation] Centre for Health Protection. 28th February

4 Background Pre-exposure prophylaxis (PrEP) Daily pill containing two HIV drugs (TDF/FTC) To prevent HIV infection Efficacy in MSM: 86% [PROUD] / 99%[iPrEx] World Health Organization (WHO) recommendation (2016): Oral pre-exposure prophylaxis (PrEP) containing TDF should be offered as an additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention approaches (strong recommendation, high-quality evidence) Anderson PL, et al. Emtricitabine-tenofovir exposure and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125. McCormack S, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016; 387(10013): Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach - Second edition. 4 Geneva: World Health Organization; 2016.

5 Background PrEP is currently unavailable in Hong Kong 1.12% (5/444) MSM had taken PrEP before [unpublished] 5

6 Background In order to facilitate PrEP promotion and implementation, understanding factors associated with awareness and acceptance is crucial 6

7 Objective To assess the role of different variables, particularly HIV testing, in affecting awareness and acceptance of PrEP among Hong Kong MSM 7

8 Methods An online self-administered survey was conducted for 2 months Variables were dichotomised and categorised into 5 groups Demographics Considerations when seeking partners Networking patterns Sexual behaviours PrEP-related factors 8

9 Methods PrEP-related factors Awareness Acceptance Assuming the degree of recognition, efficacy, price, and safety are identical, which PrEP regimen do you prefer the most? Daily Time-driven Event-driven Injectable Would not consider taking PrEP Service model 9

10 Methods φ coefficient was measured for each variable pair T-test was used to assess directional correlation Correlations with p<0.01 were regarded significant 10

11 Methods Network approach Node: Factor Edge: Significant correlation Variable A Variable B Variable C Variable E Variable F Variable D 11

12 Methods Factors with direct significant association with awareness or acceptance of PrEP were included in the network as a node Correlations between all these factors were also added to the network Variable A Variable B Variable C Acceptance of PrEP Awareness of PrEP Variable D 12

13 Methods Betweenness centrality of a node was assessed to identify important variables in the factor network The normalised number of all-pairs shortest paths passing through a node

14 Results A total of 444 MSM without known HIV infection were recruited Aug Sep variables established 804 significant links (13% of all possible links [aka density]) 14

15 Results Demographics Networking patterns Considerations when seeking partners Sexual behaviours PrEP-related factors Negative association Positive association Legend 15

16 Results Negative association Positive association 0.00 Betweenness centrality Legend

17 Conclusions Engagement in HIV testing plays an important role in one s acceptance of PrEP 17

18 Conclusions Sexual health-conscious MSM accepted PrEP, but their risk levels and the needs of PrEP are not known 18

19 Conclusions Effective dissemination of information relating to sexual health depends on the understanding of the pattern of MSM s networking channels There is a need to introduce PrEP through specific platforms to raise the community s awareness 19

20 Conclusions Integrating pre-prep screening (including, for example, risk assessment) and referral in community-based testing services could be an important strategy to achieve HIV prevention 20

21 Acknowledgements Funding agency Research Grants Council of Hong Kong (RGC Ref. No.: ) Technical support Li Ka Shing Institute of Health Sciences 21

22 PA_3 #08 The end Thank you for your attention

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments There are two options for accessing the audio portion of this webinar: (1) Using your

More information

Moving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?

Moving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP? Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are

More information

PrEP for Women: HIV Prevention in Family Planning Settings

PrEP for Women: HIV Prevention in Family Planning Settings National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov

More information

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure

More information

PrEP efficacy the evidence

PrEP efficacy the evidence PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine

More information

Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention

Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention Dawn K. Smith, MD, MS, MPH Centers for Disease Control and Prevention The findings and conclusions in this presentation have not been formally

More information

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update

More information

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000. Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD

More information

Using anti-hiv drugs for prevention

Using anti-hiv drugs for prevention Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment

More information

Drug development in relation to PrEP and the PROUD study

Drug development in relation to PrEP and the PROUD study Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals

More information

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated

More information

Pre-exposure Prophylaxis for HIV Prevention

Pre-exposure Prophylaxis for HIV Prevention Mountain West AIDS Education and Training Center Pre-exposure Prophylaxis for HIV Prevention Concerns about PrEP: Sexual Behavior and STIs Joanne Stekler, MD MPH May 19, 2016 This presentation is intended

More information

The HIV Prevention Pill: The State of PrEP Science and Implementation

The HIV Prevention Pill: The State of PrEP Science and Implementation The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the

More information

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017 HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359

More information

IAPAC Summit Daily And Intermittent PrEP

IAPAC Summit Daily And Intermittent PrEP IAPAC Summit 2012 Daily And Intermittent PrEP Six Clinical Trial Sites Nyanga District Population: 500 000 Unemployment: 70% Shack dwelling 50% Background The Global iprex Study Design Double blind,

More information

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

On the Horizon for Consideration: Biomedical Advances in HIV Prevention On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council

More information

Multiple choice questions: ANSWERS

Multiple choice questions: ANSWERS Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible

More information

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018

The Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018 The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and

More information

Case Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016

Case Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin

More information

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments

Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments Welcome to the National Association of County and City Health Officials Webinar on PrEP and Local Health Departments There are two options for accessing the audio portion of this webinar: (1) Using your

More information

HIV PREVENTION. ETHICAL CONSIDERATIONS IN DEVELOPING AN EVIDENCE BASE FOR PrEP IN PREGNANT WOMEN

HIV PREVENTION. ETHICAL CONSIDERATIONS IN DEVELOPING AN EVIDENCE BASE FOR PrEP IN PREGNANT WOMEN HIV PREVENTION ETHICAL CONSIDERATIONS IN DEVELOPING AN EVIDENCE BASE FOR PrEP IN PREGNANT WOMEN Kristen Sullivan, PhD, MSW Margaret Little, PhD Anne D. Lyerly, MD HIV & pregnancy Approximately 17.8 million

More information

Biomedical Prevention Update Thomas C. Quinn, M.D.

Biomedical Prevention Update Thomas C. Quinn, M.D. Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global

More information

Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know

Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know ANTONIO E. URBINA, MD Medical Director Associate Professor of Medicine Mt. Sinai Hospital Disclosure

More information

PrEP in the Real World: Clinical Case Studies

PrEP in the Real World: Clinical Case Studies PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program

More information

WHO s early release guidelines on PrEP: implications for emtct. Dominika Seidman, MD October 13, 2015

WHO s early release guidelines on PrEP: implications for emtct. Dominika Seidman, MD October 13, 2015 WHO s early release guidelines on PrEP: implications for emtct Dominika Seidman, MD October 13, 2015 Outline Evidence behind WHO early release guidelines on PrEP PrEP eligibility according to the WHO Rationale

More information

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/

More information

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled

More information

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP 1 2 3 17 February 2011 EMA/86004/2011 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Concept paper on the guidance on the non-clinical and clinical development of medicinal products for

More information

Overview of ARV-based prevention trials

Overview of ARV-based prevention trials Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical

More information

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time. PrEP for Women Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is PrEP? PrEP stands for Pre- Exposure Prophylaxis: Prophylaxis: Taking

More information

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987

More information

Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults

Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults Clinical Commissioning Policy Proposition: Pre-exposure prophylaxis (PrEP) to prevent the acquisition of HIV in adults Reference: NHS England F03X06 First published: TBC Prepared by NHS England Specialised

More information

South African Guidelines for the Safe Use of. Dr. Oscar Radebe

South African Guidelines for the Safe Use of. Dr. Oscar Radebe South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &

More information

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000

More information

HIV Pre-Exposure Prophylaxis (PrEP)

HIV Pre-Exposure Prophylaxis (PrEP) HIV Pre-Exposure Prophylaxis (PrEP) A Crash Course For General Practitioners Vincent Cornelisse BSc(Hons) MBBS FRACGP FAChSHM(RACP) Sexual Health Physician Prahran Market Clinic & Melbourne Sexual Health

More information

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure

More information

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory

More information

PrEP Dosing Strategies

PrEP Dosing Strategies PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity

More information

Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination

Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Be PrEPared! Using PrEP as Harm Reduction Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Ricky Hill, MA, PhD candidate Team Lead, Community Partnerships and Engagement

More information

Government of Canada Federal AIDS Initiative Milestones

Government of Canada Federal AIDS Initiative Milestones HIV in Canada: Trends and Issues for Advancing Prevention, Care, Treatment and Support Through Knowledge Exchange Michael R Smith, Senior Policy Advisor, Programs and Coordination Division, Centre for

More information

Pre-exposure Prophylaxis (PrEP)

Pre-exposure Prophylaxis (PrEP) Pre-exposure Prophylaxis (PrEP) Kenneth Mayer, MD Fenway Health Beth Israel Deaconess Medical Center Harvard Medical School and School of Public Health Treatment As Prevention in Africa Workshop May 2

More information

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow

More information

CROI 2015: HIV Prevention Updates

CROI 2015: HIV Prevention Updates NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2015: HIV Prevention Updates Ruanne V Barnabas, MBChB Dphil Global Health and Medicine University of Washington a bevy of new studies quelled most remaining

More information

CATIE STATEMENT. on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV

CATIE STATEMENT. on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV CATIE STATEMENT on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV The consistent and correct use of oral Truvada as pre-exposure

More information

Moving PrEP Forward. Where We Are & Where We Need to Go. Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases

Moving PrEP Forward. Where We Are & Where We Need to Go. Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases Moving PrEP Forward Where We Are & Where We Need to Go Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases Overview Recent study results & some context o o o Epidemiology

More information

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants. Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose

More information

Derivation of population mixing patterns from virus sequence data and their impacts on the modelling of HIV epidemics in MSM

Derivation of population mixing patterns from virus sequence data and their impacts on the modelling of HIV epidemics in MSM Derivation of population mixing patterns from virus sequence data and their impacts on the modelling of HIV epidemics in MSM Ngai Sze WONG 1 ; Tsz Ho KWAN 2 ; Kenny CW CHAN 3 ; Owen TY TSANG 4 ; Man Po

More information

Pre-exposure prophylaxis (PrEP)

Pre-exposure prophylaxis (PrEP) FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.

More information

Zero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium

Zero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium Zero HIV infections Zero HIV deaths Zero HIV stigma Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium Number of New HIV Diagnoses Overall decline in new HIV diagnoses and death in San

More information

Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location

Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations Study name and location ADAPT (HPTN 067) South Africa, Thailand, US (Harlem) Bangkok Tenofovir

More information

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,

More information

Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations

Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations Kevin Ard, MD, MPH Brigham and Women s Hospital The Fenway Institute Boston, MA Funding: The New England

More information

Combination prevention: Public health and human rights imperatives

Combination prevention: Public health and human rights imperatives Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination

More information

Guidelines for PrEP in PWID

Guidelines for PrEP in PWID Guidelines for PrEP in PWID Any use of injection drugs (past 6 months) AND Any sharing of injection equipment OR participation in methadone, naloxone, or buprenorphine treatment program (past 6 months)

More information

Unmet Oral Health Needs of Persons Living With HIV/AIDS in the United States

Unmet Oral Health Needs of Persons Living With HIV/AIDS in the United States Unmet Oral Health Needs of Persons Living With HIV/AIDS in the United States What Can We Do To Improve Services? Nicholas G. Mosca, DDS, DrPH CrescentCare Health/NO AIDS Task Force April 25, 2017 National

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

HIV Clinical Update- HIV prevention

HIV Clinical Update- HIV prevention HIV Clinical Update- HIV prevention 18 th Australian and New Zealand Conference on Haemophilia and Rare Bleeding Disorders, Melbourne October 13 th 2017 Edwina Wright Disclosures None in the past 12 months

More information

STIs in the Indian Country

STIs in the Indian Country STIs in the Indian Country Multiple STI s and Risk for HIV Ryan Kreisberg, MPH Senior Epidemiologist, PRISM Data Manager Agenda STI/HIV Trends across the US and Arizona STIs in the Indian Country Multiple

More information

Understanding the Results of VOICE

Understanding the Results of VOICE CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the

More information

PrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014

PrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014 PrEP and Behavioral Strategies for HIV Prevention Douglas Krakower, MD January 30, 2014 Potential Competing Interests Dr. Krakower: investigator-initiated research regarding HIV prevention National Institutes

More information

emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd

emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada ) SMC No. (1225/17) Gilead Sciences Ltd 10 March 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of

More information

Oral pre-exposure prophylaxis (PrEP)

Oral pre-exposure prophylaxis (PrEP) FACTSHEET Oral pre-exposure prophylaxis (PrEP) Summary Oral pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected

More information

HIV Prevention Strategies HIV Pre-exposure prophylaxis

HIV Prevention Strategies HIV Pre-exposure prophylaxis HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those

More information

Pre-exposure Prophylaxis and Primary Care

Pre-exposure Prophylaxis and Primary Care Pre-exposure Prophylaxis and Primary Care National Latino HIV and Hepatitis C Conference June 7 th, 2016 Allison Finkenbinder, MSN, WHNP-BC Denver Prevention Training Center Who s in the audience? Disclosures

More information

Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies

Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies Antiretroviral Pharmacology for PrEP: Enhancing RCT Understanding with Small Intensive Studies Craig W. Hendrix, MD Director, Drug Development Unit Division of Clinical Pharmacology Johns Hopkins University

More information

Pre-Exposure Prophylaxis PrEP where are we now? Marie Laga Institute of Tropical Medicine

Pre-Exposure Prophylaxis PrEP where are we now? Marie Laga Institute of Tropical Medicine Pre-Exposure Prophylaxis PrEP where are we now? Marie Laga Institute of Tropical Medicine New HIV diagnoses Belgium 2014 Treatment of STIs Treatment as prevention Condoms Oral preexposure prophylaxis PrEP

More information

BLT mice in HIV prophylaxis

BLT mice in HIV prophylaxis BLT mice in HIV prophylaxis Martina Kovarova, Ph.D. Assistant Professor UNC at Chapel Hill September 18, 2017 BLT mice Bone Marrow-Liver-Thymus Melkus, et al., Nature (2006) BLT humanized mice preparation

More information

HHS Public Access Author manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 01.

HHS Public Access Author manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2017 August 01. PrEP adherence patterns strongly impact individual HIV risk and observed efficacy in randomized clinical trials Dobromir T. DIMITROV, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research

More information

Mortimer Market Centre, London. Dr Margaret Portman. Date : September 2016

Mortimer Market Centre, London. Dr Margaret Portman. Date : September 2016 Dr Mags Portman Mortimer Market Centre, London Speaker Name Statement Dr Margaret Portman None Declared Date : September 2016 PrEP - Tackling Implementation Dr Mags Portman Mortimer Market Centre 15 th

More information

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5

More information

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none

More information

Sexual Health reproduction in reference to treatment as/for prevention

Sexual Health reproduction in reference to treatment as/for prevention Sexual Health reproduction in reference to treatment as/for prevention The reasons for sexual reproductive health for PLHIV The number of people living with HIV (PLWH) continues to rise in the UK The increase

More information

Ready, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico

Ready, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico Ready, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico Objectives At the end of the talk the audience should be able to: Understand

More information

Good care for people with HIV. Rights and Wrongs. Jane Anderson. May 2013

Good care for people with HIV. Rights and Wrongs. Jane Anderson. May 2013 Good care for people with HIV. Rights and Wrongs Jane Anderson May 2013 Recognition 1981-91 Intervention 1991-2001 Stabilisation 2001-2012 HIV in evolution Crisis management Palliative care Discovery Assessing

More information

2020 Vision: making England s HIV prevention response the best in the world

2020 Vision: making England s HIV prevention response the best in the world DISCUSSION PAPER 2020 Vision: making England s HIV prevention response the best in the world Introduction Effective HIV prevention makes good public health and economic sense. HIV remains one of the fastest-growing

More information

The New HIV Epidemic Challenges: Policy, Politics, and Poor Patients

The New HIV Epidemic Challenges: Policy, Politics, and Poor Patients The New HIV Epidemic Challenges: Policy, Politics, and Poor Patients John T. Carlo, MD, MS Chief Executive Officer AIDS ARMS, INC. https://twitter.com/jtcarlo Conflict of Interest None 2 Learning Objectives

More information

Biomedical Prevention in HIV

Biomedical Prevention in HIV Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa

More information

The role of Integrase Inhibitors during HIV prevention

The role of Integrase Inhibitors during HIV prevention The role of Integrase Inhibitors during HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 2nd Global HIV Clinical Forum: Integrase Inhibitors Paris July 22th

More information

Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination

Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination Harlan Pruden Educator, Chee Mamuk, Aboriginal Program BC Center for Disease Control, Clinical Prevention Services Sḵwx on the traditional, ancestral

More information

A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)

A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017 Presentation

More information

Strategic use of antiretroviral drugs to prevent HIV transmission

Strategic use of antiretroviral drugs to prevent HIV transmission Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases

More information

HIV Pre- Exposure Prophylaxis

HIV Pre- Exposure Prophylaxis HIV Pre- Exposure Prophylaxis KNOWLEDGE AND ATTITUDES IN NORTH QUEENSLAND GENERAL PRACTITIONERS Principle Investigator: William Lane Co-Supervisor 1: Professor Clare Heal Co-Supervisor 2: Dr Jennifer Banks

More information

PrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine

PrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine PrEP and npep for HIV Prevention Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine Case Study A 26 y/o M presents for routine asymptomatic screening for sexually transmitted infections

More information

Malaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh

Malaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival

More information

UK community perspective on PrEP and PROUD. Simon Collins

UK community perspective on PrEP and PROUD. Simon Collins UK community perspective on PrEP and PROUD Simon Collins Overview Community perspective on PrEP: 3 myths and 5 community issues (Glasgow) The PROUD study and UK experience Update from CROI - February 2015

More information

during conception, pregnancy and lactation at 2 U.S. medical centers

during conception, pregnancy and lactation at 2 U.S. medical centers Use of HIV preexposure prophylaxis during conception, pregnancy and lactation at 2 U.S. medical centers Dominika Seidman, MD Shannon Weber, Maria Teresa Timoney, Karishma Oza, Elizabeth Mullins, Rodney

More information

TasP - Individual versus Public Health Benefit versus Both.

TasP - Individual versus Public Health Benefit versus Both. Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We

More information

Los Angeles County PATH: PrEP and TLC+ for HIV Prevention. PATH Community Advisory Board Member Application

Los Angeles County PATH: PrEP and TLC+ for HIV Prevention. PATH Community Advisory Board Member Application Los Angeles County PATH: PrEP and TLC+ for HIV Prevention PATH Community Advisory Board Member Application We would like to invite you to become a member of the PrEP and TLC+ for HIV Prevention (PATH)

More information

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics

More information

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples

More information

Strategies for Using Pre-Exposure Prophylaxis (PrEP) to Lower HIV Incidence in Select Populations

Strategies for Using Pre-Exposure Prophylaxis (PrEP) to Lower HIV Incidence in Select Populations Strategies for Using Pre-Exposure Prophylaxis (PrEP) to Lower HIV Incidence in Select Populations Policy Considerations and Suggestions of the National PrEP Committee: Project Inform, AIDS Vaccine Advocacy

More information

Syphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Syphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Syphilis Key facts In 2015, 28 701 syphilis cases were reported in 29 EU/EEA Member States (data were not available from Austria and Liechtenstein),

More information

PEP and PrEP: AWAAC 2014

PEP and PrEP: AWAAC 2014 Acknowledgements: HIVCS PEP guidelines group, Helen Rees, Slim Abdool Karim, Quarraisha Abdool Karim, Clinical Care Options, Edwina Wright, Jared Baeton, AETC PEP and PrEP: AWAAC 2014 Francois Venter Wits

More information

Can we treat our way out of the HIV epidemic?

Can we treat our way out of the HIV epidemic? Can we treat our way out of the HIV epidemic? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University Schoolboy s (and politician s) tricks for evading the question

More information

Shebeen Attendees Perceptions of HIV Pre-Exposure Prophylaxis (PrEP) in KwaZulu-Natal Province, South Africa

Shebeen Attendees Perceptions of HIV Pre-Exposure Prophylaxis (PrEP) in KwaZulu-Natal Province, South Africa Shebeen Attendees Perceptions of HIV Pre-Exposure Prophylaxis (PrEP) in KwaZulu-Natal Province, South Africa Katie Kuenzle Yale University Philanjalo Background: HIV Prevalence South Africa has the largest

More information

Ending the Epidemic: What Clinicians Need to Know

Ending the Epidemic: What Clinicians Need to Know Ending the Epidemic: What Clinicians Need to Know Mary Goodspeed, RN, BS Coordinator, HIV Clinical Education Erie County Medical Center 716-898-4713 LEARNING OBJECTIVES: 1. List the three points of the

More information

Cutting Edge and Interventions of Promote PrEP Adherence. Martin Hoenigl, MD; University of California San Diego

Cutting Edge and Interventions of Promote PrEP Adherence. Martin Hoenigl, MD; University of California San Diego Cutting Edge and Interventions of Promote PrEP Adherence Martin Hoenigl, MD; University of California San Diego Adherence and Risk for Incident Sexually Transmitted Infection among Methamphetamine using

More information

Is this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health

Is this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health Is this the end of AIDS? New advances in HIV prevention. James McIntyre Anova Health Institute and University of Cape Town School of Public Health Thirty years of AIDS July 3, 1981 A generation in the

More information

10/05/2016. PrEP : from proof of concept to real life. E. CUA Nice university hospital

10/05/2016. PrEP : from proof of concept to real life. E. CUA Nice university hospital PrEP : from proof of concept to real life E. CUA Nice university hospital 1 Disclosures Received honoraria and acted as consultant : Merck, Gilead, ViiV Co-investigator: Merck, Gilead, ViiV and BMS phase

More information